8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                  ------------
                                    FORM 8-K
                                  ------------
                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

                Date of Report (Date of Earliest Event Reported):
                                 January 6, 2004

                           USANA HEALTH SCIENCES, INC.
             (Exact name of registrant as specified in its charter)

                           Commission File No. 0-21116

             Utah                                           87-0500306

(State or other jurisdiction of                    (IRS Employer Identification
        incorporation)                                        Number)

                           3838 West Parkway Boulevard
                           Salt Lake City, Utah 84120
               (Address of principal executive offices, Zip Code)

       Registrant's telephone number, including area code: (801) 954-7100

   Former name or former address, if changed since last report: Not Applicable



Item 9.  Regulation FD Disclosure

On January 6, 2004, USANA Health Sciences, Inc. issued a press release updating
its estimate for sales and earnings per share for the fourth quarter and fiscal
2003. The press release dated January 6, 2004 updated the previous sales and
earnings per share guidance provided by the company in a press release dated
October 14, 2003, previously furnished on Form 8-K. A copy of the press release
dated January 6, 2003 is furnished herewith as Exhibit 99.1 to this Form 8-K and
is incorporated herein by reference. The company will also post the press
release on its corporate website, www.usanahealthsciences.com under the
"investor relations" link.

The information in this Current Report is being furnished and shall not be
deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section.
The information in this Current Report shall not be incorporated by reference
into any registration statement or other document pursuant to the Securities Act
of 1933, as amended. The furnishing of the information in this Current Report is
not intended to, and does not, constitute a representation that such furnishing
is required by Regulation FD or that the information this Current Report
contains is material investor information that is not otherwise publicly
available.

                                       2



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                    USANA HEALTH SCIENCES, INC.


                                    By:  /s/ Gilbert A. Fuller
                                         ---------------------
                                    Gilbert A. Fuller, Chief Financial Officer

Date: January 6, 2004

                                       3

EX-99

                                                                    Exhibit 99.1

                USANA Provides Preliminary Fourth Quarter Results

    SALT LAKE CITY--(BUSINESS WIRE)--Jan. 6, 2004--USANA Health
Sciences Inc. (NASDAQ: USNA) announced today the preliminary results
for the fourth quarter of 2003.
    Sales are expected to be approximately $59 million for the quarter
ending Jan. 3, 2004 and will total about $200 million for the fiscal
year. Earnings per share for the fourth quarter are expected to be
approximately $0.32 on a fully diluted basis, of which about $0.02 is
attributable to an adjustment of the company's effective tax rate for
2003. Earnings per share for the fiscal year ended Jan. 3, 2004 are
expected to be about $0.98. These amounts are adjusted to reflect the
2-for-1 forward split of the company's stock effected in October 2003.
    Commenting on the fourth quarter, Gilbert A. Fuller, USANA's chief
financial officer, said, "We are expecting to achieve record sales and
earnings in the fourth quarter and we are very pleased with these
results. Our expected fourth quarter sales growth of more than 50
percent is driven by continued growth in the number of active
Associates in both domestic and international markets. Our expected
earnings per share growth of more than 100 percent illustrates
efficiencies generated by our operations. USANA's commitment to
producing the highest quality, scientifically proven nutritional
supplements that are safe and effective continues to create strong
market response and fuel our optimism about the future."
    USANA plans to announce its final fourth quarter and year-end
results on Feb. 3, 2004; executives will hold a conference call with
investors on Feb. 4, 2004.
    USANA develops and manufactures high-quality nutritionals,
personal care, and weight management products that are sold directly
to Preferred Customers and Associates throughout the United States,
Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea,
Singapore and the United Kingdom. More information on USANA can be
found at http://www.usanahealthsciences.com.

    This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Actual results could differ materially from
those projected in the forward-looking statements, which involve a
number of risks and uncertainties, including reliance upon the
company's independent Associate network, government regulation of
products, manufacturing and marketing, the possible continued spread
of severe acute respiratory syndrome (SARS) in Asia, and risks
associated with international expansion. The contents of this release
should be considered in conjunction with the warnings and cautionary
statements contained in USANA's most recent filings with the
Securities and Exchange Commission on Forms 10-Q and 10-K.


    CONTACT: USANA Health Sciences Inc., Salt Lake City
             Riley Timmer, 801-954-7100
             investor.relations@us.usana.com